vs
Ultragenyx Pharmaceutical Inc.（RARE）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Resolute Holdings Management, Inc.的1.8倍（$207.3M vs $117.7M），Resolute Holdings Management, Inc.净利率更高（-1.5% vs -62.0%，领先60.6%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $-100.8M）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
RARE vs RHLD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $117.7M |
| 净利润 | $-128.6M | $-1.7M |
| 毛利率 | — | 55.7% |
| 营业利润率 | -54.7% | 30.2% |
| 净利率 | -62.0% | -1.5% |
| 营收同比 | 25.9% | — |
| 净利润同比 | 3.5% | — |
| 每股收益（稀释后） | $-1.28 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $207.3M | $117.7M | ||
| Q3 25 | $159.9M | $120.9M | ||
| Q2 25 | $166.5M | $119.6M | ||
| Q1 25 | $139.3M | $103.9M | ||
| Q4 24 | $164.6M | — | ||
| Q3 24 | $139.5M | — | ||
| Q2 24 | $147.0M | — | ||
| Q1 24 | $108.8M | — |
| Q4 25 | $-128.6M | $-1.7M | ||
| Q3 25 | $-180.4M | $-231.0K | ||
| Q2 25 | $-115.0M | $-611.0K | ||
| Q1 25 | $-151.1M | $-3.4M | ||
| Q4 24 | $-133.2M | — | ||
| Q3 24 | $-133.5M | — | ||
| Q2 24 | $-131.6M | — | ||
| Q1 24 | $-170.7M | — |
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -54.7% | 30.2% | ||
| Q3 25 | -106.9% | 34.3% | ||
| Q2 25 | -64.8% | 34.0% | ||
| Q1 25 | -102.6% | 24.7% | ||
| Q4 24 | -74.3% | — | ||
| Q3 24 | -94.6% | — | ||
| Q2 24 | -79.1% | — | ||
| Q1 24 | -151.9% | — |
| Q4 25 | -62.0% | -1.5% | ||
| Q3 25 | -112.8% | -0.2% | ||
| Q2 25 | -69.0% | -0.5% | ||
| Q1 25 | -108.5% | -3.2% | ||
| Q4 24 | -80.9% | — | ||
| Q3 24 | -95.7% | — | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -156.8% | — |
| Q4 25 | $-1.28 | $-0.20 | ||
| Q3 25 | $-1.81 | $-0.03 | ||
| Q2 25 | $-1.17 | $-0.07 | ||
| Q1 25 | $-1.57 | $-0.39 | ||
| Q4 24 | $-1.34 | — | ||
| Q3 24 | $-1.40 | — | ||
| Q2 24 | $-1.52 | — | ||
| Q1 24 | $-2.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $-80.0M | $6.5M |
| 总资产 | $1.5B | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $205.5M | ||
| Q3 25 | $202.5M | $148.0M | ||
| Q2 25 | $176.3M | $99.9M | ||
| Q1 25 | $127.1M | $71.0M | ||
| Q4 24 | $174.0M | — | ||
| Q3 24 | $150.6M | — | ||
| Q2 24 | $480.7M | — | ||
| Q1 24 | $112.3M | — |
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-80.0M | $6.5M | ||
| Q3 25 | $9.2M | $10.8M | ||
| Q2 25 | $151.3M | $9.6M | ||
| Q1 25 | $144.2M | $8.9M | ||
| Q4 24 | $255.0M | — | ||
| Q3 24 | $346.8M | — | ||
| Q2 24 | $432.4M | — | ||
| Q1 24 | $140.3M | — |
| Q4 25 | $1.5B | $333.4M | ||
| Q3 25 | $1.2B | $293.2M | ||
| Q2 25 | $1.3B | $253.3M | ||
| Q1 25 | $1.3B | $214.3M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | $189.2M |
| 自由现金流率自由现金流/营收 | -48.6% | 160.8% |
| 资本支出强度资本支出/营收 | 0.5% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-472.0M | $313.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-99.8M | $196.1M | ||
| Q3 25 | $-91.4M | $59.6M | ||
| Q2 25 | $-108.3M | $48.9M | ||
| Q1 25 | $-166.5M | $18.4M | ||
| Q4 24 | $-79.3M | — | ||
| Q3 24 | $-67.0M | — | ||
| Q2 24 | $-77.0M | — | ||
| Q1 24 | $-190.7M | — |
| Q4 25 | $-100.8M | $189.2M | ||
| Q3 25 | $-92.7M | $58.6M | ||
| Q2 25 | $-110.7M | $47.5M | ||
| Q1 25 | $-167.8M | $17.8M | ||
| Q4 24 | $-79.5M | — | ||
| Q3 24 | $-68.6M | — | ||
| Q2 24 | $-79.0M | — | ||
| Q1 24 | $-193.9M | — |
| Q4 25 | -48.6% | 160.8% | ||
| Q3 25 | -58.0% | 48.5% | ||
| Q2 25 | -66.5% | 39.7% | ||
| Q1 25 | -120.5% | 17.1% | ||
| Q4 24 | -48.3% | — | ||
| Q3 24 | -49.2% | — | ||
| Q2 24 | -53.7% | — | ||
| Q1 24 | -178.2% | — |
| Q4 25 | 0.5% | 5.8% | ||
| Q3 25 | 0.8% | 0.8% | ||
| Q2 25 | 1.5% | 1.2% | ||
| Q1 25 | 1.0% | 0.6% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 3.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RHLD
暂无分部数据
